News
Galectin Therapeutics Issues Statement on GR-MD-02 Development Program
July 30, 2014 | Press ReleaseGalectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis
July 25, 2014 | Press ReleaseGalectin Therapeutics Announces First Patient Dosed in Cohort 1 of Phase 1B Clinical Trial of GR-MD-02 in Combination with Ipilimumab in Metastatic Melanoma
July 22, 2014 | Press ReleaseGalectin Therapeutics Added to Russell 2000 Index
July 9, 2014 | Press ReleaseHighlights
View a presentation from detailing second cohort results of Phase 1 clinical trial of GR-MD-02 in NASH
July 30, 2014 | PresentationView Galectin Therapeutics’ webcast discussing second cohort results of Phase 1 clinical trial of GR-MD-02 in NASH
July 30, 2014 | WebcastView a New York Times article highlighting Galectin Therapeutics’ role in the fight against fatty liver disease
June 16, 2014 | News ArticleView a video recording of the 2014 Annual Stockholder Meeting
May 21, 2014 | WebcastView a presentation from the 2014 Annual Stockholder Meeting
May 14, 2014 | Presentation
Galectin Therapeutics, Inc.
NASDAQ: GALT
6.19-0.41 Stock price updates every 30 minutes.